Skip to main content
. 2022 Apr 12;62:103800. doi: 10.1016/j.msard.2022.103800

Fig. 1.

Fig 1

(A) SARS-CoV-2 IgG Spike titre (median with IQR) in MS subjects treated with different DMTs, 5–6 months after the second vaccine dose (T2) compared to healthy controls (HC). Wilcoxon two-tailed test vs HC subjects was performed and a p-value less than 0.05 was considered statistically significant. * p<0.05; **p<0.01; ****p<0.0001. (B) SARS-CoV-2 IgG Spike titre kinetics (mean ± SEM) of MS subjects treated with different DMTs at 21 days (T1) and 5–6 months (T2) after the second vaccine dose, compared to HC. Wilcoxon two-tailed test was performed to compare T1 and T2 levels and a p-value less than 0.05 was considered statistically significant. * p<0.05; **p<0.01; *** p<0.005; ****p<0.0001. (C) Fold percentage of SARS-CoV-2 IgG Spike titre persistance (mean ± SEM) of MS subjects treated with different DMTs at T2, relative to HC (100%). Wilcoxon two-tailed test vs HC subjects was performed and a p-value less than 0.05 was considered statistically significant. * p<0.05; ****p<0.0001.